Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06242249
Other study ID # 74932
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date April 30, 2024
Est. completion date June 30, 2026

Study information

Verified date March 2024
Source Shahid Beheshti University of Medical Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Immunotherapy has shown promise in the treatment of hematological malignancies, including multiple myeloma. One approach is CAR-NK cell therapy, which involves genetically modifying natural killer (NK) cells to target specific cancer antigens. While CAR-NK therapy offers advantages over CAR-T therapy, such as reduced immune system reactions and lower production time and cost, challenges remain in terms of antitumor efficacy and the tumor microenvironment. Preclinical and early clinical studies have targeted various antigens, including BCMA, with CAR-NK cells in multiple myeloma. To further investigate the potential of BCMA-targeted CAR-NK cell therapy, this study aims to evaluate its safety and determine the maximum tolerated dose (MTD) in patients who have not responded to standard therapy.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 10
Est. completion date June 30, 2026
Est. primary completion date April 30, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Age 18-80 years with expected survival > 3 months. 2. Confirmed diagnosis of active multiple myeloma with detectable BCMA expression in malignant cells. 3. Relapsed or refractory disease with at least 2 prior lines of treatment, including a proteasome inhibitor and immunomodulator, without achieving significant efficacy. 4. Measurable disease at screening according to IMWG criteria, as defined by any of the following: Serum monoclonal paraprotein (M-protein) level =1.0 g/dL or urine M-protein level being as defined; or light chain MM without measurable disease in the serum or the urine; serum immunoglobulin free light chain disease dL and abnormal serum immunoglobulin kappa/lambda free light chain ratio 5. ECOG performance status of 0-1. 6. Acceptable cardiac, liver, and kidney function. 7. Signed written informed consent. Exclusion Criteria: 1. Pregnant or lactating women. 2. Uncontrolled active infection, HIV infection, or positive syphilis serology reaction. 3. Active hepatitis B or hepatitis C infection. 4. Recent or current use of glucocorticoids or other immunosuppressors. 5. Severe cardiac, liver, renal insufficiency, diabetes, or other diseases. 6. Participation in other clinical research in the past three months.

Study Design


Intervention

Biological:
Anti-BCMA CAR-NK
Ten eligible patients with relapsed refractory multiple myeloma will be enrolled based on inclusion criteria and informed consent. After conditioning with Fludarabine and Cyclophosphamide, patients will receive a single infusion of BCMA CAR NK cells with close monitoring using one of the following dose levels: Dose Level 1: 1×10^7/Kg Dose Level 2: 5×10^7/Kg Dose Level 3: 1×10^8/Kg Safety Assessment: Adverse events will be recorded and graded. Laboratory parameters and cytokine release syndrome (CRS) markers will be closely monitored. Efficacy Evaluation: Response assessments will follow IMWG guidelines, including complete response (CR), partial response (PR), stable disease (SD), and progressive disease.

Locations

Country Name City State
Iran, Islamic Republic of Shariati Hospital Tehran

Sponsors (1)

Lead Sponsor Collaborator
Shahid Beheshti University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of dose-limiting toxicity (DLTs) Incidence of dose-limiting toxicity (DLTs) within 4 weeks after infusion, characterized by >= Grade 3 signs/symptoms according to CTCAE v4.03, to assess safety and tolerability. 4 weeks
Primary Assessment of Maximum Tolerated Dose (MTD) 4 weeks
Primary Overall Remission Rate (ORR) Overall Remission Rate (ORR) two months after infusion, assessed using International Myeloma Working Group (IMWG) criteria. 8 weeks
Secondary Progression-free survival (PFS) Progression-free survival (PFS) for up to 12 months, assessed using IMWG criteria. 48 weeks
Secondary Duration of Response (DOR) Duration of Response (DOR) for up to 12 months, assessed using IMWG criteria. 48 weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06411301 - A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors Phase 1
Recruiting NCT05008536 - Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma Early Phase 1
Recruiting NCT06158412 - All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma Phase 2
Recruiting NCT05121103 - A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma Phase 1
Recruiting NCT04603872 - CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies Early Phase 1
Recruiting NCT04657861 - APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma Early Phase 1
Terminated NCT05191472 - Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies Phase 2
Active, not recruiting NCT04688853 - A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients Phase 1
Not yet recruiting NCT05050305 - Marizomib Central Nervous System (CNS) Phase 2
Recruiting NCT05546723 - LMY-920 for Treatment of Relapsed or Refractory Myeloma Phase 1
Not yet recruiting NCT06115135 - A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma Phase 2
Not yet recruiting NCT06225310 - A Trial of Selinexor, Ruxolitinib and Methylprednisolone Phase 1
Recruiting NCT05673083 - Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
Completed NCT02176213 - Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma Phase 2
Enrolling by invitation NCT04861480 - Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma Phase 1
Completed NCT06012383 - Alvocade® (Bortezomib) Safety and Effectiveness Study
Not yet recruiting NCT05909826 - Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM Phase 2
Recruiting NCT04414475 - A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM Phase 2
Completed NCT04811898 - A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment Phase 1
Recruiting NCT05739188 - Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM Phase 1/Phase 2